Daiichi Sankyo has formalised a strategic agreement with Tempus AI aimed at accelerating the clinical trajectory and differentiation of an antibody drug conjugate programme within oncology. The collaboration centres on integrating advanced AI capabilities into drug development workflows, with Daiichi Sankyo leveraging Tempus’ foundation models, including PRISM2, to extract diagnostic and predictive insights from combined pathology imaging and clinical datasets. This move reflects a broader shift toward embedding data-driven methodologies into oncology pipelines.
At the core of the partnership is the alignment of Daiichi Sankyo’s clinical trial and preclinical research datasets with Tempus’ extensive real-world data infrastructure. Through this integration, both companies intend to expand biomarker discovery initiatives and refine patient stratification strategies. The effort is expected to generate actionable intelligence that enhances trial design and improves therapeutic targeting. In this context, the AI oncology collaboration is positioned as a mechanism to unlock deeper clinical insights while advancing precision medicine objectives.
Both organisations will jointly develop proof-of-concept AI models designed to optimise patient selection and improve success rates for emerging ADC candidates. These models will be deployed across Tempus’ oncology database, producing detailed response maps that enable more precise patient segmentation and facilitate benchmarking of control arms in future trials. The AI oncology collaboration is therefore expected to influence not only early-stage research but also downstream clinical execution.
Tempus data and apps CEO Ryan Fukushima said: Our collaboration with Daiichi Sankyo signals a new chapter in how multimodal AI and real-world data can be applied to advance the development of ADCs.
Our multimodal foundation models seek to radically accelerate and improve our ability to uncover unmet patient needs and identify patients most likely to benefit from novel therapies.
Applying AI in clinical development isn’t just about efficiency any more, leading companies like Daiichi Sankyo are using these models to enhance the design of more targeted, impactful clinical trials.
Tempus continues to focus on advancing precision medicine through AI-enabled healthcare solutions, supporting both clinical decision-making and therapeutic development. The collaboration builds on earlier industry engagements, including a multi-year agreement between Boehringer Ingelheim and Tempus AI announced in May 2025 to advance oncology pipelines. That prior engagement similarly underscored the role of AI and integrated data ecosystems in reshaping cancer research and development.
